A phase 1, multicenter, open-label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged 6 to <12 years) with a history of migraine
Authors:
Posted in Papers / Human Studies|Original Research / October 16-31, 2025
Headache. 2025 Oct 24. doi: 10.1111/head.15074. Online ahead of print.
PMID: 41133671 | DOI: 10.1111/head.15074
Share this article
Sign Up For An MSC Newsletter
Register to Watch the MSC Emerging Science Contest!
The MSC Emerging Science Contest for Young Investigators will take place on Wednesday, December 13, 2023, from 8-10 PM Eastern (US) time. We welcome those who wish to watch the event as an attendee. Register here to attend, and learn more about the contest here.